Floatz logo

Etx-19477

BRCA2 Mutation

858 Therapeutics, Inc.Phase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

30 Active assets in the BRCA2 Mutation cohort.

Asset / SponsorPhaseRating
Olaparib
M.D. Anderson Cancer Center
Phase 3BB
Veliparib
The University of Texas Health Science Center at San Antonio
Phase 2BB
Talzenna
Brown University
Phase 3BB
Olaparib
GBG Forschungs GmbH
Phase 3BB
Ovitrelle
University Hospital, Ghent
Phase 4BB

View all 50 →

Same molecule, other indications

Etx-19477 is also rated in:

estrogen-receptor positive breast cancerDormant
CC
Indicative ·
47 / 100
View asset →
castration-resistant prostate carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
breast-ovarian cancer, familial, susceptibility to, 1Dormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →